StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.30−0.02 (-0.60%)

Close on Nov 18, 2026Market cap $263.35MP/E –Yield –

Prelude Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Prelude Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$33.26M. For fiscal 2025 it was -$56.37M. The highest annual figure on record is -$26.45M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$56.37M–
FY2024Dec 31, 2024-$103.65M–
FY2023Dec 31, 2023-$110.58M–
FY2022Dec 31, 2022-$86.75M–
FY2021Dec 31, 2021-$85.85M–
FY2020Dec 31, 2020-$46.80M–
FY2019Dec 31, 2019-$26.45M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.57M–
Q1 FY2026Mar 31, 2026-$21.69M–
Q4 FY2025Dec 31, 2025$23.12M–
Q3 FY2025Sep 30, 2025-$19.12M–
Q2 FY2025Jun 30, 2025-$26.10M–
Q1 FY2025Mar 31, 2025-$34.28M–
Q4 FY2024Dec 31, 2024-$20.80M–
Q3 FY2024Sep 30, 2024-$27.36M–
Q2 FY2024Jun 30, 2024-$23.42M–
Q1 FY2024Mar 31, 2024-$32.08M–
Q4 FY2023Dec 31, 2023-$24.71M–
Q3 FY2023Sep 30, 2023-$26.27M–
Q2 FY2023Jun 30, 2023-$28.65M–
Q1 FY2023Mar 31, 2023-$30.94M–
Q4 FY2022Dec 31, 2022-$23.32M–
Q3 FY2022Sep 30, 2022-$21.36M–
Q2 FY2022Jun 30, 2022-$19.23M–
Q1 FY2022Mar 31, 2022-$22.85M–
Q4 FY2021Dec 31, 2021-$26.00M–
Q3 FY2021Sep 30, 2021-$22.43M–
Q2 FY2021Jun 30, 2021-$20.29M–
Q1 FY2021Mar 31, 2021-$17.13M–
Q4 FY2020Dec 31, 2020-$15.18M–
Q3 FY2020Sep 30, 2020-$12.68M–
Q2 FY2020Jun 30, 2020-$8.94M–
Q1 FY2020Mar 31, 2020-$10.00M–
Q4 FY2019Dec 31, 2019-$8.67M–

More Prelude Therapeutics figures

See a number that looks wrong?